Filtered By:
Source: Clinical Cancer Research
Nutrition: Hawthorn
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1 results found since Jan 2013.
MAPK Pathway Inhibitors Sensitize BRAF Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB.
CONCLUSIONS: The combination of MAPK pathway inhibitors with an antibody-drug-conjugate targeting GPNMB is an effective therapeutic option for patients with melanoma.
PMID: 27515299 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - August 10, 2016 Category: Cancer & Oncology Authors: Rose AA, Annis MG, Frederick DT, Biondini M, Dong Z, Kwong LN, Chin L, Keler T, Hawthorne T, Watson IR, Flaherty KT, Siegel PM Tags: Clin Cancer Res Source Type: research
